Overview
Novel TRPV1 Agonist Prodrugs for Pain
Overview
Novel TRPV1 Agonist Prodrugs for Pain
We are developing a portfolio of novel, non-opioid therapeutics that provide long-lasting pain relief after a single local administration.
Attributes
Attributes of our prodrugs
Attributes
Attributes of our prodrugs
Reduced opioid consumption & opioid-related adverse events
NON-OPIOID
Targets pain at source with limited systemic exposure
SITE SPECIFIC
Single injection simplifies ongoing care
SIMPLE
Continuous and durable relief
LONG-LASTING
PAIN-SELECTIVE
Extended pain relief without numbness or weakness
The Problem
The Problem
The Problem
The Problem
Current Postsurgical Treatment Options Fall Short
THERE IS NO "GOOD" WAY TO PROVIDE CONTINUOUS, EFFECTIVE PAIN RELIEF BEYOND THE FIRST 18-24 HOURS AFTER SURGERY.
Treating pain systemically with opioids provides relief but dramatically increases costs and morbidity
Treating pain at its source with local anesthetic is effective, but limited by its short duration of action
Treating pain with regional blocks is highly effective, but duration is less than 24 hours and relief is accompanied by muscle weakness and sensory numbness
Despite Advances In Cancer Treatment, Cancer Pain Continues To Be A Problem With A Heavy Reliance On Opioids
Pain is the most feared symptom with cancer (Jain 2015)
Overall pain prevalence is 33% (more than 75% with advanced disease) (Paice 2011)
Severe pain prevalence is 5% (increases with advanced disease) and predicts near-term hospitalizations (Wagner-Johnston 2010)
Opioids, while the mainstay of treatment, are limited by side effects
Eventually, conservative treatments fail and require invasive approaches which are costly
There Are Few Durable, Effective and Safe Treatment Options For Moderate To Severe Osteoarthritis (OA) Pain
THERE IS NO “GOOD” WAY TO PROVIDE DURABLE, EFFECTIVE RELIEF FOR MODERATE TO SEVERE OSTEOARTHRITIS PAIN.
NSAIDS only effective for mild-to-moderate and have significant safety issues (GI, Renal, CV)
Opioids provide limited, short-term relief but dramatically increase costs and morbidity
Intra-articular (IA) steroids are somewhat effective yet limited due to short duration of action
IA hyaluronic acid has limited differentiation from placebo in controlled clinical studies
Goal
Goal
Goal
Goal
Our goal is to drive the actualization of value-based health care by substantially reducing costs, improving outcomes and reducing complexity of care.
DECREASE OPIOID USE AND HARMFUL, COSTLY SEQUELAE
REDUCE DAILY PAIN AND INCREASE MOBILITY
REDUCE LOST-DAYS-OF-WORK AND HASTEN RETURN TO PRODUCTIVITY
REDUCE UNNECESSARY HOSPITAL COSTS INCLUDING: DECREASE TIME TO DISCHARGE AND DECREASE ER VISITS AND RE-ADMITTANCE